Chemoimmunomodulation of MDSCS as a novel strategy for cancer therapy

9Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Tumor-induced myeloid-derived suppressor cells (MDSCs) are a critical barrier to effective immunotherapy of cancer. We identified that Docetaxel and a natural compound, Icariin, can target MDSCs with preferential apoptosis of M2 cells and polarization of the surviving cells towards M1 cells. Such strategic targeting of MDSCs restored T cell function accompanied by tumor retardation in vivo. © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Djeu, J., & Wei, S. (2012). Chemoimmunomodulation of MDSCS as a novel strategy for cancer therapy. OncoImmunology. https://doi.org/10.4161/onci.1.1.18074

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free